Cyclophosphamide induces durable molecular and clinical responses in patients with relapsed T-LGL leukemia.

Authors

Zachary Braunstein, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, United States
Eric McLaughlin, Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, United States
Anjali Mishra, Department of Medical Oncology, Sydney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States; Department of Cancer Biology, Sydney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, United States
Jonathan E Brammer, Division of Hematology, Department of Internal Medicine, James Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States

Document Type

Editorial

Publication Date

4-26-2022

Comments

This article is the author's final published version in Blood Advances, Volume 6, Issue 8, April 2022, Pages 2685 - 2687.

The published version is available at https://doi.org/10.1182/bloodadvances.2021006263.

Copyright © 2022 by The American Society of Hematology.

Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Recommended Citation

Braunstein, Zachary; McLaughlin, Eric; Mishra, Anjali; and Brammer, Jonathan E, "Cyclophosphamide induces durable molecular and clinical responses in patients with relapsed T-LGL leukemia." (2022). Department of Medical Oncology Faculty Papers. Paper 184.
https://jdc.jefferson.edu/medoncfp/184

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

34996100

Language

English